临床前医药研发服务
Search documents
本周2只新股申购!“中国版英伟达”启动打新
Zheng Quan Shi Bao· 2025-11-24 00:26
Group 1 - The core viewpoint of the news is the upcoming IPOs of two companies on the Sci-Tech Innovation Board, namely Moer Thread and Bai Ao Sai Tu, with significant fundraising goals and innovative technology focus [1][2][3]. Group 2 - Moer Thread is set to launch its IPO on November 24, with an issue price of 114.28 yuan per share, making it the highest-priced IPO of the year, aiming to raise approximately 75.76 billion yuan after deducting issuance costs [1]. - The company specializes in the research, design, and sales of full-function GPU products, positioning itself as a domestic leader in both graphics rendering and AI computing, often referred to as the "Chinese version of Nvidia" [1]. - The funds raised will be allocated to the development of next-generation AI training and inference chips, graphics chips, and AI SoC chips, as well as to supplement working capital [2]. - Bai Ao Sai Tu will initiate its IPO on November 28, aiming to raise 1.185 billion yuan, and is a preclinical CRO and biotechnology company that utilizes its proprietary gene editing technology for drug development services [2][3]. - Bai Ao Sai Tu is transitioning to an A+H listing, having already been listed on the Hong Kong Stock Exchange since September 2022 [3].
年内第一高价新股,摩尔线程今日申购!
Zheng Quan Shi Bao· 2025-11-24 00:17
Group 1: Company Overview - Moer Thread is a leading company in the domestic GPU sector, recognized for its full-function GPU R&D capabilities, and will become the "first domestic GPU stock" upon listing [1][2] - The company has successfully launched four generations of GPU architecture, covering various application fields including AI computing, high-performance computing, and graphics rendering [2] - Baiaosaitu is a preclinical CRO and biotechnology company that provides innovative animal models and preclinical drug development services based on its proprietary gene editing technology [3][4] Group 2: Financial Performance - Moer Thread's projected revenues for 2022, 2023, and 2024 are 0.46 billion, 1.24 billion, and 4.38 billion respectively, with net losses of -1.894 billion, -1.703 billion, and -1.618 billion [2] - Baiaosaitu's projected revenues for the same years are 0.534 billion, 0.717 billion, and 0.98 billion, with net losses of -0.602 billion, -0.383 billion, and a profit of 0.034 billion in 2024 [4] Group 3: Fundraising and Investment Plans - Moer Thread plans to use the funds raised for the development of next-generation AI training and inference chips, graphics chips, and AISoC chips, as well as to supplement working capital [2] - Baiaosaitu intends to invest the raised funds in early-stage drug development service platform construction, antibody drug R&D and evaluation projects, and preclinical R&D projects [4]
国产GPU巨头来了!年内第一高价股
Zhong Guo Zheng Quan Bao· 2025-11-23 04:09
Group 1: New Stock Offerings - Two new stocks will be available for subscription on the Sci-Tech Innovation Board next week: Moer Thread on November 24 and Bai Ao Sai Tu on November 28 [1] - Moer Thread's offering price is set at 114.28 yuan per share, making it the highest IPO price this year, with a total fundraising target of 8 billion yuan [1][2] - Moer Thread is expected to become the "first domestic GPU stock" upon listing, with a total market capitalization projected to reach 53.7 billion yuan [2] Group 2: Moer Thread Company Overview - Moer Thread focuses on the research, design, and sales of GPUs and related products, aiming to provide computing acceleration platforms for high-performance computing fields such as AI and digital twins [2] - The company has launched four generations of GPU architectures since its establishment in 2020, but has not yet achieved profitability, reporting losses from 2022 to 2025 [2] Group 3: Bai Ao Sai Tu Company Overview - Bai Ao Sai Tu is a leading company in the field of model animals, focusing on preclinical research and biotechnology services [3] - The company utilizes its proprietary gene editing technology to provide innovative model animals and drug development services, and has been listed in Hong Kong since 2022 [3] - Bai Ao Sai Tu has shown revenue growth from 5.34 billion yuan in 2022 to an expected 9.80 billion yuan in 2024, with a net profit turning positive in 2025 [3]